Immunity against pneumococcal infections is impaired in older people, and current vaccines are 15 poorly protective against pneumococcal disease in this population. Naturally-acquired immunity 16 against pneumococcal capsular polysaccharides develops during childhood and is robust in young 17 adults, but deteriorates with advanced age. In particular, antibody levels and function are reduced 18 in older people. Pneumococcal vaccines are recommended for people over 65 years of age. 19
Introduction 26
Streptococcus pneumoniae, or the pneumococcus, is a major cause of morbidity and mortality in the 27 elderly. People aged over 65 experience up to a five-fold increase in the incidence and mortality of 28 pneumococcal community-acquired pneumonia (CAP) relative to those aged under 65 (1, 2) . In the 29 United States, an estimated 600,000 episodes of pneumococcal CAP occur annually, with a total cost 30 to society of US$4.85bn (3); hospitalizations for pneumococcal CAP are predicted to increase by 31 nearly 100% by the year 2040, with 87% of this increase accounted for by the elderly (4). In 32 resource-rich settings, pneumococcal meningitis is becoming a disease of the elderly (5, 6) and 33 frequently results in death or long-term sequelae, with higher mortality in the elderly than any other 34 age-group (7, 8) . Pneumococcal bacteremia is associated with substantial mortality whether in 35 isolation or when associated with confirmed organ infection, and is associated with increased 36 incidence and mortality in the elderly (9, 10) . 37
Throughout history, humans have suffered from pneumococcal disease and the pneumococcus has 38 evolved in parallel with our immune systems (11). The first effective treatment for pneumococcal 39 disease was passive immunotherapy: the transfer of specific immune serum from naturally-immune 40 donors or immunized animals to patients with pneumococcal pneumonia (12) . Alongside antibiotic 41 therapy, pneumococcal vaccines represent a signal success in humanity's battle against the 42 pneumococcus. Opsonizing anti-capsular polysaccharide (CPS) antibodies are a recognized correlate 43 of protection and are common to both the natural and vaccine-induced responses against 44 pneumococcal disease; therefore in this review we focus on this facet of adaptive immunity. In the 45 first part of this review we discuss pneumococcal colonization, naturally-acquired anti-CPS immunity, 46 and how these change during adulthood. In the second part we focus on the response to 47 pneumococcal vaccination in the elderly. We conclude with an overview of mucosal immunity in the 48 elderly, a summary of important knowledge gaps, emerging strategies, and priorities for future 49 research. Although we focus on anti-CPS antibodies, it must be emphasized that successful defense 50 on April 27, 2017 by University of Liverpool Library http://cvi.asm.org/ Downloaded from testing positive by any method) to as high as 23% in an elderly population (20) , or 34% if saliva is also 75 sampled (21) . 76
Thus, while classical microbiological analysis on nasopharyngeal samples from elderly subjects may 77 not have as high a yield as molecular analysis of oral or salivary specimens, it has the advantage of 78 allowing a more direct comparison with previous studies. It may be simplistic to report PCR as 79 "more sensitive" than culture, as the clinicopathological significance of low-density, culture-negative 80 colonization may not be equivalent to that of high-density, culture-positive colonization. Similarly, 81 the presence of pneumococcal DNA in the oropharynx may not represent the presence of viable 82 pneumococci in the nasopharynx. 83
Most importantly, high nasopharyngeal colonization rates in elderly people (23%, as defined by 84 classical culture) have been demonstrated during an outbreak in a nursing home (25), suggesting 85 that culture-positive nasopharyngeal colonization may be a clinically relevant measurement in the 86 elderly. 87
In this Review, for the reasons outlined above and to introduce an element of homogeneity when 88 comparing studies of children, adults, older adults and mice, we will define colonization as the 89 isolation of pneumococci from the nasopharynx by culture-based methods. 90
Pneumococcal colonization and naturally-acquired anti-pneumococcal immunity: an age-dependent 91 phenomenon 92
The link between pneumococcal colonization (or carriage) and the subsequent development of all 93 forms of pneumococcal disease is generally accepted, being biologically plausible and supported by 94 experimental murine models of meningitis, studies of children with otitis media and adults with 95 pneumonia (23, 26, 27) . However, colonization may be a necessary evil: exposure to pneumococcal 96 antigens via repeated episodes of nasopharyngeal colonization is key to acquiring and sustaining 97 anti-pneumococcal immunity. 98 6 Throughout childhood, adolescence and early adulthood, immunity against pneumococcus improves 99 with age. Children aged under two years have high rates (over 60%) of nasopharyngeal 100 pneumococcal colonization (28, 29) . Up to 15% of colonization episodes progress to clinical disease 101 (particularly otitis media) before an immune response can clear the pathogen, which could be 102 explained by the lack of a robust anti-CPS immune response in young children (23, 30, 31) . 103
Colonization rates fall with increasing age, along with a corresponding reduction in pneumococcal 104 disease (28). It seems that repeated colonization episodes lead to the development of protective 105 immunity against the most prevalent circulating pneumococcal serotypes (anti-CPS antibodies are, in 106 general, specific to a given serotype) (32). Following the maturation of the immune system and 107 multiple episodes of colonization, young adults have well-functioning immune systems and 108 established serotype-specific immunologic memory (33). 109
Naturally-acquired immunity is multifactorial: non-specific anti-pneumococcal immunity develops 110 alongside serotype-specific immunity in children, through mechanisms that have not been entirely 111 elucidated (34). In young infants with immature anti-CPS responses, epidemiological studies have 112 suggested that non-specific immunity predominates (35), while serotype-specific immunity comes to 113 the fore in older children (32). In adulthood, both epidemiologic and controlled human infection 114 studies have suggested that serotype-specific immunity plays a major role (33, 36) . We hypothesize 115 that anti-pneumococcal immunity in older adults is more akin to that of young adults than to that of 116 infants. 117
Young adults experience very low morbidity and mortality from pneumococcal disease (e.g. 3.1 cases 118 annually per 100,000 population, versus 38.6 cases per 100,000 population in children aged under 119 one year) (8), and their serotype-specific immunity is boosted by occasional episodes of 120 asymptomatic colonization (33, 36, 37) . However, in old age, a paradox emerges: while 121 nasopharyngeal colonization appears to be less common in older adults (see TABLE 1) , they are at 122 extremely high risk of pneumococcal disease. 123 on April 27, 2017 by University of Liverpool Library http://cvi.asm.org/
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One hypothesis suggests that the same mechanism (immunosenescence) determines increasing 124 disease susceptibility with reduced colonization: increased circulating levels of pro-inflammatory 125 cytokines ("inflammaging") could lead to clearance of colonization before a natural boosting of pre-126 existing immunity could take place (38) (39) (40) . An alternative explanation is that colonization is under-127 detected in this age-group and that it is a precursor to disease, which cannot be prevented by the 128 senescent elderly immune system. Mucosal immunity may be more durable than systemic humoral 129 immunity (to be discussed in detail later)-this could explain a protection against colonization but 130 susceptibility to invasive disease. Regardless, older adults are clearly at high risk of pneumococcal 131 disease, and therefore their natural anti-pneumococcal immunity must differ from that of younger 132 adults. Declines in both innate and adaptive immunity combined with increased rates of 133 comorbidities all contribute to this (41), but we will focus here on antibody-mediated immunity. 134
Naturally-acquired pneumococcal CPS antibodies: an overview 135 As outlined above, natural immunity arises following episodic colonization. Colonization leads to 136 increased serum levels of anti-pneumococcal antibodies, which are detectable in all adults (42, 43). 137 In this section we will discuss their role in the control of pneumococcal disease. Anti-CPS antibodies 138 are the most widely-studied antibodies and are the direct effectors of vaccine-induced protection, 139 and therefore we focus on these. 140
In addition to antibodies generated by natural colonization, others have reported on naturally-141 arising polyvalent antibodies (often IgM) with potent anti-pneumococcal activity (44)-whether 142 these antibodies are analogous to those that arise following colonization is unclear. Furthermore, it 143 is possible that these antibodies undergo refinement and increased specification over time, 144 stimulated by antigen presentation (45) . For this review we will define naturally-acquired antibodies 145 as those that arise following pneumococcal exposure. the classical complement pathway; in murine models this appears to be the dominant complement 150 pathway in anti-pneumococcal immunity and is mediated via natural IgM rather than IgG (46). 151
Antibodies are a key product of nasopharyngeal colonization and protect against disease 152
They are particularly effective in control of bloodstream infections: passive transfer of human 153 antibodies (generated following experimentally-induced colonization) was protective in a murine 154 model of lethal bacteremia (36). Passive transfer of pre-colonization serum from the same human 155 volunteers conferred a lesser survival benefit. In a separate murine lethal challenge model, CD4-156 deficient knockout mice were able to mount a protective antibody response following experimental 157 colonization and survive subsequent bacteremic challenge, whereas antibody-deficient knockout 158 mice had no survival benefit from prior colonization (47). Experimental colonization of mice also 159 generated a protective response against subsequent pneumonia (22). However, this experiment 160 found that all arms of the innate and adaptive immune systems were required for protection: 161 depletion of any of B cells, neutrophils or CD4 cells eliminated the protective response. This 162 suggests that the control of mucosal disease is more complex than the control of bloodstream 163 disease. Thus, based on the evidence accumulated from a combination of murine and human 164 challenge models, antibodies induced by pneumococcal colonization have been shown to confer 165 protection against bacteremia and contribute to protection against pneumonia. 166
Clearance of colonization is a complex process 167
Antibodies have an important role in the protection against becoming colonized. In mice, passive 168 transfer of antibodies lead to agglutination of bacteria following intranasal challenge, which causes 169 the bacteria to clump and become more vulnerable to mucociliary clearance (48). Pneumococcal 170 antibody-mediated agglutination has also been demonstrated in humans following vaccination with 171 pneumococcal conjugate vaccine (PCV) (49). In this study, naturally-acquired antibodies were 172 present in the nasopharynx prior to vaccination, but not in sufficient levels to induce agglutination. 173 on April 27, 2017 by University of Liverpool Library http://cvi.asm.org/
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Murine studies have suggested that the clearance of established colonization is primarily mediated 174 by CD4 cells and interleukin 17 (IL-17), with a possible contribution from anti-protein antibodies (50-175 52). Thus, it appears that anti-CPS antibodies generated during a colonization episode do not have a 176 role in its clearance, though they may be protective against the future acquisition of colonization 177 and subsequent development of disease. This role of anti-CPS antibodies is supported by clinical 178 studies demonstrating the virtual elimination of vaccine-serotype pneumococcal colonization in 179 vaccinated children (53). The functional importance of anti-CPS antibodies is summarized in Figure 1 . degree as in younger subjects. B1 cells are another potential culprit; these cells are responsible for 201 producing naturally-acquired anti-CPS antibodies (while T cell-dependent adaptive antibodies are 202 generated by B2 cells). Levels of B1 cells are reduced in the elderly (reviewed in (56)). This is an 203 emerging field, and there is a dearth of human studies relevant to this topic outside of the context of 204 vaccination-we will explore this in a later section. 205
Antibodies decline and lose functional efficacy with age. 206 Figure 2 shows a schematic of anti-CPS antibody levels and function at different ages relative to 207 rates of pneumococcal colonization and disease. Population-based studies have shown that natural 208 anti-CPS IgG and IgM levels fall with age (42, 57, 58) . Antibody function, i.e. opsonic activity, can 209 vary markedly between individuals; populations with high rates of pneumococcal colonization and 210 disease have higher serum opsonic activity than lower-risk populations, even when matched for age 211 and antibody level (59). For this reason, opsonophagocytic killing activity is accepted as a better 212 correlate of protection than antibody levels (60). It is therefore of greater importance that the 213 naturally-acquired anti-CPS antibodies of older people have less opsonic activity than those of young 214 people. In one study, the concentration of natural serotype-specific IgG required for 50% opsonic 215 killing was up to twice as high in an unvaccinated elderly population when compared with a young 216 population-differences in IgG function between young and old were even more substantial than 217 differences in concentrations (54). Similar, though less pronounced differences were seen for IgM. 218
The authors noted that serotype-specific IgM concentrations and opsonic activity were poorly 219 correlated, unlike those of IgG. When the decline in antibody level and function are combined, this 220 strongly suggests that antibody defects are responsible for (or at least contribute towards) the age-221 related increase in vulnerability to pneumococcus. 222 on April 27, 2017 by University of Liverpool Library http://cvi.asm.org/ Downloaded from Impaired opsonic functionality relative to antibody levels is seen in immunosuppression secondary 223 to a wide variety of etiologies. Although not directly comparable to the elderly, it is notable that 224 anti-CPS IgG levels in HIV-infected individuals (who have high rates of pneumococcal colonization as 225 well as disease) have been shown to be higher than those of HIV-uninfected subjects, but with 226 reduced opsonic activity (61). 227
An observational study provides some clinical context and supports the hypothesis that reduced 228 opsonic functionality in anti-CPS antibodies is a risk factor for pneumococcal disease in the elderly. 229
Sera from patients in the acute and convalescent stages of various types of pneumococcal disease 230 were compared with age-matched controls (62). Only 27% of subjects with pneumococcal disease 231 had IgG to their infecting serotype at time of presentation (compared to 37% of controls and 42% of 232 colonized subjects). Furthermore, acute antibodies from infected subjects had significantly lower 233 opsonic activity than those of controls or colonized subjects and were less protective via passive 234 transfer in a lethal murine challenge model (20% survival vs 100%). Sixty-two percent of 235 convalescent sera had detectable IgG following pneumococcal disease, which demonstrated good 236 function in >50% of patients. Important limitations of this study include substantial loss to follow-up 237 between the acute and convalescent phases, no reporting of ages, and no pre-disease antibody 238 levels, the last of which means we cannot rule out the possibility of antibody sequestration in 239 diseased tissues as an explanation for low circulating levels. 240
Most of the more detailed studies of antibody functionality in the elderly have been conducted in 241 the context of vaccination. Vaccination is an obvious strategy to restore waning natural anti-CPS 242 immunity in the elderly. 243
Vaccines against pneumococcal disease: an overview 244
The pneumococcal polysaccharide vaccine (PPV) was the first licensed vaccine against the 245 pneumococcus; PPV23 denotes the current 23-valent formulation. The pneumococcal protein-246 conjugated vaccine (PCV) has superior immunogenicity and efficacy in children; the most recent 247 on April 27, 2017 by University of Liverpool Library http://cvi.asm.org/ Downloaded from formulation is the 13-valent PCV13. Childhood vaccination programs generate herd protection by 248 reducing colonization and thus halting transmission at a population level (63). However, serotype 249 replacement has abrogated much of this benefit in many settings (64, 65) . Even without significant 250 levels of serotype replacement, vaccine type disease remains common in older people after 251 childhood vaccination programs are established (66), and residual non-vaccine-type disease will 252 persist as a public health problem (5). 253
In the USA, current recommendations for adults aged over 65 years advise vaccination with PCV13 254 followed by PPV23 (67). In the UK, PPV23 is recommended in older adults, but the addition of 255 PCV13 was not deemed to be cost-effective, and the use of PPV23 is to be kept under review (68). 256
Recommendations in other Western European countries vary considerably (69). 257
Current pneumococcal vaccination strategies provide poor protection in older adults 258
The discrepancies in national vaccination policies stem from the poor (and disputed) efficacy of 259 these vaccines in older people. A Cochrane review in 2013 concluded that PPV23 effectively 260 prevents pneumococcal bacteremia and meningitis, including in the elderly (70). It has minimal 261 effect at the mucosal level, and thus has not been shown to reduce rates of colonization. The 262
Cochrane review found no effect of PPV23 on rates of (non-bacteremic) pneumococcal CAP or all-263 cause pneumonia, partially due to the substantial heterogeneity of studies that were included. 264
Nonetheless, some individual studies-including both observational studies and well-conducted 265 randomized controlled trials (RCTs)-have found PPV23 to be efficacious against pneumococcal 266 pneumonia. For example, one double-blind RCT in elderly Japanese nursing home residents (a 267 population expected to have a high incidence of pneumonia, and therefore better positioned to 268 detect a vaccine effect) found a 62% relative risk reduction of pneumococcal pneumonia, and a 39% 269 relative risk reduction of all-cause pneumonia with PPV23 (71). When data from this study was 270 pooled with others for the Cochrane meta-analysis, the effect was no longer significant; however, 271 this does not exclude the possibility of a small protective effect against pneumococcal pneumonia 272 on April 27, 2017 by University of Liverpool Library http://cvi.asm.org/ Downloaded from from PPV23, which would be clinically significant in a high-risk population. An important limitation 273 of the Cochrane review is that the many of the studies it included were carried out in a general adult 274 population, with limited data available for age-specific subgroup analyses. 275
An important study of PPV23 in people aged ≥ 65 years has been published since the Cochrane 276 review (72). This study was observational in nature, but employed a test-negative design: this 277 reduces several biases and has been found to be similar to RCTs in providing estimates of vaccine 278 effectiveness for seasonal influenza vaccines (73). The study, carried out in Japan, found that the 279 effectiveness of PPV23 was 27·4% against all pneumococcal CAP and 33·5% against CAP caused by 280 the 23 vaccine serotypes (72). Effectiveness was not demonstrated against all-cause pneumonia or 281 mortality. Furthermore, it was notable that this effect was only statistically significant for subjects 282 who had been vaccinated within the previous two years. 283
Conjugated vaccines, while covering fewer serotypes, protect against colonization in children and 284 young adults (74, 75) . In addition to efficacy against vaccine-type bacteremia and meningitis, PCV13 285 has been shown to reduce rates of vaccine-type CAP in a single large RCT in older adults (CAPiTA) 286 (76). However, with vaccine efficacy of 45.6%, this vaccine did not show complete protection 287 against vaccine-type disease. PCV13 efficacy declined with increasing age: In a post-hoc analysis, 288 overall vaccine efficacy against vaccine-type CAP was 65% in 65-year-old subjects but only 40% in 75-289
year-olds (77). Furthermore, a concomitant increase in non-vaccine type disease was noted, 290 resulting in no effect against pneumococcal pneumonia in general, and all-cause mortality was 291 unaffected (76). 292
Pneumococcal vaccines are immunogenic in older people 293
In a study of 74 elderly subjects, dialysis patients and transplant recipients (i.e. without young 294 healthy controls), PPV23 was found to improve anti-CPS IgG levels against three selected vaccine 295 serotypes (6, 14 and 23) and not only to improve opsonic activity, but to strengthen the correlation 296 between IgG levels and opsonic activity, suggesting that vaccine-induced antibodies are more potent 297 on April 27, 2017 by University of Liverpool Library http://cvi.asm.org/ Downloaded from than naturally acquired antibodies (78). A study of 219 adults aged ≥70 years found that PCV7 was 298 more immunogenic (as measured by concentration and function of post-vaccine anti-CPS IgG) than 299 PPV23 for all but one of the PCV7 serotypes (79). However, a larger study (n = 599) of adults aged 300 50-80 years found that PCV7 and PPV23 were equally immunogenic (as defined by IgG 301 concentrations) at one month and one year following vaccination (58). No functional tests were 302 performed. The reasons for the discrepant results between these two studies remains unclear. A 303 randomized study of nursing home residents aged ≥80 years found that both PPV23 and PCV7 were 304 immunogenic in this population, with the conjugate vaccine resulting in higher IgG levels and 305 opsonic activity for some serotypes, and both vaccines equally immunogenic for others (80). The 306 effects of single-dose versus boosted vaccination, in various combinations, have been assessed in a 307 number of studies but with conflicting results (reviewed in (81)). 308
The immune responses to PPV23 across an elderly population are heterogeneous. One study has 309 suggested that a four-fold increase in IgG concentration from baseline following vaccination is 310 protective against recurrent pneumococcal CAP in the elderly (82). This study had a number of 311 limitations (including low rates of confirmed pneumococcal etiology in cases of CAP) and has not 312 been replicated. 313
The differential effects of the two vaccines on B cells have been studied extensively. In a cohort of 314 348 subjects aged 50-70 years, the antibody responses were similar to previous studies: PCV7 lead 315 to greater anti-CPS IgG concentrations than PPV23 for some but not all serotypes-four out of seven 316 in this case (83). However, serotype-specific memory B cell concentrations increased for all seven 317 serotypes following PCV7 but decreased following PPV23 (84). This is consistent with the T-318 dependent immunogenicity of PCV7. Importantly, repeated doses of unconjugated polysaccharide 319 vaccines do not result in immune boosting-rather, the antibody response is inferior to that 320 following primary vaccination (hyporesponsiveness) (85). Memory B cell depletion has been 321 implicated in this phenomenon (84), which can be avoided by spacing vaccine administrations by at 322 on April 27, 2017 by University of Liverpool Library http://cvi.asm.org/ Downloaded from least five years (86). It is unclear whether repeated natural exposure to pneumococcal antigens is 323 associated with hyporesponsiveness, but this intriguing hypothesis has been proposed as an 324 additional mechanism of pneumococcal immunodeficiency in the elderly (84) and is an important 325 topic for future research. 326
The above studies based all analyses on blood samples taken up to one month post-vaccination. 327
Another study randomized 252 subjects aged 50-80 years to vaccination with either single-dose 328 PPV23 or PCV7, or PCV boosted with either PPV23 or repeat PCV7, and followed them for two years 329 (87) . Surprisingly, there was no significant difference in the quantity of circulating serotype-specific 330 memory B cells at two years between the four groups. Two-year levels of serotype-specific memory 331 and plasma cells were closely correlated with baseline serotype-specific IgG levels, and not with the 332 IgG levels from 7 or 28 days post-vaccination. The authors concluded that pre-existing natural anti-333 pneumococcal immunity was a more important driver of the post-vaccine immune response than 334 the type or schedule of vaccine administered. No functional assays were carried out, and there were 335 no young adult control subjects, but this remains an important study. It is unclear why these authors 336 found no difference in memory B cell concentrations between PPV and PCV-vaccinated subjects 337 while other authors found a dramatic difference (84) Pneumococcal vaccination is more immunogenic in young people than in elderly people 354
One study compared anti-CPS antibody levels in 58 volunteers aged >65 years and 44 controls aged 355 <45 years, 28 days after they had received PPV23 (no pre-vaccination levels were taken) (90). For 356 the majority of serotypes, antibody levels did not differ significantly between the two groups. 357
However, opsonic titers against all but one serotype (18C) were markedly higher in the younger 358 subjects. Antibody potency (opsonization titer divided by the antibody concentration) was at least 359 two-fold higher for all serotypes in younger subjects than in elderly subjects, while the amount of 360 antibody needed to achieve a 1:8 opsonization index (a putative protective level) in young subjects 361 was less than half of that in the elderly subjects. Thus, while uncontrolled studies had shown an 362 improved antipneumococcal immune response following vaccination in elderly people, this is far less 363 impressive than the immune response generated by the same vaccine in healthy young people. 364
We are unaware of any direct comparison studies of the immunogenicity of PCV in older and 365 younger people. Murine studies have explored this question, but the results were markedly 366 different from with what would be expected in human subjects based on the state of current 367 knowledge, and will therefore not be discussed here (91). 368
Anti-CPS IgM responses are markedly deficient in older people 369
In one study, the authors acquired sera from 45 healthy elderly subjects and 55 healthy young 370 controls, all of whom had been vaccinated four weeks previously with PPV23, and tested them 371 on April 27, 2017 by University of Liverpool Library http://cvi.asm.org/ Downloaded from against three representative serotypes: 14, 18C and 23F (92). In keeping with previous studies, 372 absolute anti-CPS IgG levels were similar between both groups, but the younger adults had higher 373 opsonic activity and potency than the older subjects (albeit not achieving statistical significance for 374 serotype 18C). Young adults commonly demonstrated high levels of opsonic activity even with low 375 levels of antibody (i.e. the correlation between antibody levels and opsonic activity was poor), 376 whereas in the elderly antibody levels and activity were tightly correlated. IgM made a 377 disproportionately significant contribution to opsonic activity: when IgM was removed from the 378 young subjects' samples, their opsonic activity was decreased, with stronger correlation between 379 their IgG levels and opsonic function. When all serum samples were depleted of IgM and 380 reanalyzed, the opsonic activity of the elderly sera did not decline and the differences in opsonic 381 activity between old and young subjects were no longer statistically significant. The authors 382 concluded that reduced functionality of IgM rather than IgG was responsible for the reduced opsonic 383 capacity of elderly subjects when compared with younger subjects. 384
The kinetics of IgM could partially explain the above findings: unlike IgG, post-vaccination IgM levels 385 rise more slowly, and to a lower peak, in elderly subjects compared with younger subjects (93). All 386 samples in the above study were taken quite soon after vaccination. Little is known regarding the 387 duration of IgM responses in the elderly beyond 28 days post-vaccination, and thus the relevance of 388 this laboratory-based study to long-term clinical protection is not certain. However, additional 389 research has shown that the underlying IgM B cell responses to vaccination, in addition to IgM 390 activity itself, are also diminished in the elderly. 391
A study comparing fourteen elderly subjects with young controls examined the immune response 392 against two of the PPV23 serotypes (14 and 23F) and found that serotype 14-specific IgM did not rise 393 significantly following vaccination in the elderly (though anti-23F IgM did) (94). Opsonic activity 394 improved following vaccination in the elderly, and this was correlated with IgG levels but not with 395 (41)). Therefore, alterations in T-dependent immunity coupled with a reduction in T-407 independent IgM memory B cells leaves elderly people vulnerable on two fronts. 408
IgM defects are unlikely to be the sole reason for the increased susceptibility of elderly people to 409 pneumococcal disease. However, by virtue of its pentameric structure, IgM would be expected to 410 agglutinate and opsonize more efficiently than IgG, and thus even small defects in IgM levels or 411 function would be expected to have a disproportionate impact. IgM is also key to activating the 412 complement cascade in response to pneumococcus (46). While the IgM response to PCV has not 413 been widely studied in the elderly, it is key to the immune response to conjugated vaccines in 414 children (96). Furthermore, PCV-induced IgM antibodies appear to confer cross-protection against 415 some non-vaccine serotypes in children (97)-this has not been demonstrated in the elderly, but 416 could represent another domain in which IgM is of key importance. For now, the above data must 417 be regarded as hypothesis-generating rather than conclusive, but they are intriguing nonetheless. 418
Antibodies have mucosal as well as systemic activity 419
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It is generally reported that IgM and IgA are the principal antibodies present at mucosal surfaces (98, 420 99), although the relative contributions of different globulin fractions to total antibody levels varies 421 markedly between different organ systems (100). IgA-mediated defense against pneumococcus is 422 limited, as all pneumococci synthesize an efficient IgA1 protease, abrogating its protective effect 423 (48). In the final part of this review, we will briefly explore the nature of mucosal anti-pneumococcal 424 immunity and its relationship with age. 425
There is a degree of overlap between the mucosal and systemic humoral immune systems, and each 426 is capable of influencing the other (99). Antigens from the nasal mucosal surface are presented to 427 nasopharyngeal-associated lymphoid tissue (NALT), leading to both local and systemic immune 428 responses. Germinal centers in NALT are responsible for generating B cells that secrete IgA and IgM 429 at the mucosal surface. Furthermore, systemic antibodies can be transported from blood to mucosal 430
surfaces. 431
Systemic exposure to pneumococcal antigens via vaccination can lead to mucosal protection 432
One study found that PPV leads to an increase in levels of all classes of anti-CPS in secretions 433 (specifically saliva and tears; nasal secretions were not studied) (101). Notably, the fold increases in 434 salivary IgG (4.5-fold) and IgM (4.0-fold) were more pronounced than that of IgA (2.0-fold). 435 However, the functional and clinical effects of these antibodies have not been explored. 436
In young adults, systemic immunization with PCV13 leads to high serum concentrations of anti-437 pneumococcal IgG, which spills over into the nasal mucosal compartment and can, by virtue of its 438 agglutinating properties, prevent the development of pneumococcal colonization (49). This is likely 439 to be the mechanism for the reduction in pneumococcal colonization following infant vaccination. 440 Detailed studies of mucosal immunosenescence in general have only been undertaken in mice: it 468 appears that nasal immune function deteriorates with age, but at a similar rate to systemic 469 immunity, whereas intestinal immunity mucosal "ages" at a faster rate (104). Murine studies have 470 demonstrated impaired innate antipneumococcal nasal mucosal immunity with increasing age, 471 primarily stemming from macrophage dysfunction (105). Nasal antibodies have not been studied in 472 elderly humans, but salivary antipneumococcal antibodies have been shown to decrease in both 473 concentration and rate of secretion with age (106). We are currently recruiting a cohort of older 474 adults who will undergo experimental human pneumococcal inoculation (ISRCTN ID 10948363) in 475 order to inform our understanding of colonization dynamics, natural antibody generation and 476 nasopharyngeal mucosal immune responses in this population. 477
Murine studies of adjuvanted mucosal pneumococcal vaccines have shown promise 478
Studies of mucosal vaccination strategies against pneumococcus have only been undertaken in 479 murine models (reviewed in (107)) and examined both protein antigens and CPS. The most 480 intriguing findings from these studies have been the effect of novel adjuvants on restoring the 481 immune response in aged mice to both protein and polysaccharide antigens. Addition of CpG 482 oligodeoxynucleotides (CpG-ODN) was found to improve the systemic and mucosal antibody 483 response to conjugated pneumococcal serotype 9V CPS administered nasally to young mice (108). 484
CpG-ODN enhances antibody production through stimulation of type 1 helper T cells; the underlying 485 mechanism of this remains uncertain (109). This same adjuvant restored the antibody response of 486 aged mice to conjugated serotype 14 CPS administered systemically (110). For nasally-administered 487 pneumococcal surface protein A (PspA), a dual adjuvant strategy of CpG-ODN and plasmid-488 expressing Flt3 ligand was required to induce similar antibody levels (serum and mucosal IgG and 489 IgA) in young and old mice (111). This strategy also enhanced PspA-specific CD4 + T-cell responses in 490 old mice and was protective against nasopharyngeal colonization in these mice. 491
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It must be emphasized that mouse IgA, having a different configuration to human IgA, is less 492 susceptible to cleavage by pneumococcal IgA protease. Thus, if the above findings are to have 493 applicability for human vaccination, it will be essential to demonstrate either that antibodies are a 494 dispensable component of the mucosal immune response, or that other immunoglobulins-such as 495 secretory IgM and IgG-are sufficient for protection in humans. If the relative dysfunction of anti-496 CPS IgM in elderly humans is indeed of clinical significance, then this may prove to be the Achilles' 497 heel of this vaccination strategy, unless an adjuvant can be identified that can restore the function of 498 IgM in the elderly. With this caveat in mind, an appropriately-adjuvanted mucosal vaccine could still 499 have enormous potential for reducing the burden of pneumococcal disease in the elderly. 500
Alternative antibody targets 501
This review has focused on anti-CPS antibodies. These antibodies are induced by natural exposure 502 to pneumococcus and are also the antigens employed in all currently-licensed pneumococcal 503 vaccines. Furthermore, there is a substantial body of literature comparing anti-CPS immunity in 504 young and elderly adults. However, the pneumococcus also expresses a variety of surface proteins 505 which are conserved across different serotypes, many of which have been proposed as vaccine 506 candidates (112) and indeed have been explored in mucosal vaccines as outlined above. Anti-507 protein immune responses have been demonstrated following colonization (36) and may contribute 508 to naturally-acquired protection against colonization (34) although their mechanistic significance has 509 not been definitively established (113). In children, studies are conflicting regarding whether anti-510 protein antibodies confer protection or serve as a marker of exposure and increased risk of disease 511 (114, 115) . Anti-protein antibody levels are reduced in the elderly (42). Anti-protein antibody 512 levels rise following pneumococcal disease in older adults (116), and there is a suggestion that their 513 functionality may not be adversely affected by aging, though these findings remain preliminary 514 (German E et al, unpublished data) . Apart from these, and the above-mentioned murine studies of 515 on April 27, 2017 by University of Liverpool Library http://cvi.asm.org/ Downloaded from mucosal anti-protein immunity, we are unaware of any substantial body of work exploring the 516 nature of aging and anti-protein immunity, and this topic must be prioritized in future research. 517
Conclusion 518 Impaired naturally-acquired CPS immunity leaves elderly people vulnerable to pneumococcal 519 disease. The same factors responsible for this reduction in naturally-acquired immunity also result in 520 suboptimal functional antibody responses to current pneumococcal vaccines. PCV13 has overcome 521 some, but by no means all of the immunological limitations of PPV23. Reduced antibody 522 functionality combined with limited serotype coverage means that pneumococcal vaccination in the 523 elderly does not deliver as substantial a benefit as would be expected. 524
If anti-CPS antibodies are to remain the mediator of protection, then improvements in the 525 functionality of aged antibodies-particularly IgM-will need to be induced. A mucosal vaccine, with 526 an appropriate adjuvant, would be an attractive strategy. Vaccination strategies seeking to exploit 527 non-capsular antigens or T cell-mediated immunity have shown a degree of promise in early-phase 528 studies in young adults, but have yet to achieve their full potential (117). Careful studies of anti-529 protein immunity in the elderly would guide the exploration of such a vaccination strategy in older 530 adults. Future studies should investigate the dynamics of colonization and mechanisms of naturally-531 acquired immunity in the elderly in greater detail, as well as exploring the nature of respiratory 532 mucosal immunity in the elderly, in order to better inform vaccine development for this growing and 533 vulnerable population. 534 and Dr India Wheeler for their assistance with the literature review, and Patrick Lane for assistance 539 with the figures. 540
Figure 1 541
Anti-capsular antibodies can be acquired naturally (following pneumococcal exposure, e.g. 542 colonization, or through pneumococcal disease) or via vaccination. They facilitate pneumococcal 543 killing via opsonisation. In addition, they can prevent the development of colonization in the 544 future-this has been shown to be mediated via agglutination in the case of antibodies induced by 545 protein-conjugated pneumococcal vaccines. 546
Figure 2 547
Schematic of pneumococcal disease rates, pneumococcal colonization rates and pneumococcal 548 antibody activity in different age groups. Pneumococcal colonization and disease rates are high in 549 young children. Naturally-acquired pneumococcal capsular polysaccharide (anti-CPS) antibody levels 550 rise with recurrent exposure. Young adults have high levels of naturally-acquired antibodies, 551 occasional episodes of colonization and low rates of disease. In the elderly, antibody levels are low 552 and functional activity is even lower, colonization is infrequent and rates of pneumococcal disease 553 increase. 554
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